CytoDyn (CYDY) Climbs Almost 29% This Week After Getting Positive Results From Cancer Treatment: Should You Invest?

One of the stocks that have performed quite well this week is CytoDyn Inc., which saw its stock surge by 14% on Wednesday. But as of right now the stock is falling 3.3%. But the stock has been surging exponentially. CYDY stock gained 14% on Wednesday, as it traded more than 3.38 million shares.

The stock is trading at $1.8 The rally in the stock is being driven by the positive results of the company’s Phase 1b/2 trial for patients with advanced cancer. The study focused on patients with triple-negative breast cancer. It revealed that the cancer-associated macrophage cells were significantly reduced.

The company has notified that the drop was observed after patients were given leronlimab for around 30 days. As for the patients who were part of the study, they were selected for a compassionate use initiative. As per the data collected during the trials, around 72% of the patients showed a drop in macrophage-like cells, which are known as cancer-associated macrophage cells.

Agneta Johansen

Agneta is still enjoying her trips to Asia and Africa while she works at Own Snap as an author and reporter. Very soon she will settle somewhere in Europe and run her startup enterprise.

Want Hot Stocks?    Yes. I Love Them No thanks